Giselle Kohler, MD
Nephrology · Springfield, MONPI 1518285261
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Fresenius USA Marketing, Inc. accounts for 69.3% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2022 at $3,967 and has fallen 91.9% since, to $321 in 2025.
Across 98 payments — averaging $71.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$5K
- AstraZeneca$345
- Travere Therapeutics, Inc.$162
- Mallinckrodt Hospital Products Inc.$144
- Otsuka America Pharmaceutical, Inc.$142
- Bard Peripheral Vascular, Inc.$137
- plus $1K from 20 others
What the payments were for
- Consulting fees$3,40049%
- Travel & lodging$80312%
- Food & beverage$2,59837%
- Education$1672%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 8 | $4,830 |
| AstraZeneca | 13 | $345 |
| Travere Therapeutics, Inc. | 11 | $162 |
| Mallinckrodt Hospital Products Inc. | 5 | $144 |
| Otsuka America Pharmaceutical, Inc. | 5 | $142 |
| Bard Peripheral Vascular, Inc. | 1 | $137 |
| Daiichi Sankyo Inc. | 7 | $134 |
| ANI Pharmaceuticals, Inc. | 3 | $126 |
| Nxstage Medical, Inc. | 3 | $125 |
| Amgen(2 entities) | 7 | $117 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 6 | $117 |
| Boehringer Ingelheim | 6 | $107 |
| Baxter Healthcare | 3 | $102 |
| GSK | 6 | $83 |
| Aurinia Pharma U.S., Inc. | 2 | $53 |
| Vifor Pharma, Inc. | 2 | $40 |
| Ardelyx, Inc. | 1 | $33 |
| Vantive US Healthcare LLC | 1 | $29 |
| Veloxis Pharmaceuticals, Inc. | 1 | $27 |
| Calliditas Therapeutics US Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| OPKO Pharmaceuticals, LLC | 1 | $15 |
| Novartis | 1 | $14 |
| Strongbridge US Inc. | 1 | $12 |
| Mallinckrodt Enterprises LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,968 in reported general payments places this provider in the 85th percentile of 253 nephrology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 36 | $161,849 |
| AuryxiaFerric Citrate | 68 | $147,264 |
| VelphoroSucroferric Oxyhydroxide | 16 | $71,580 |
| VeltassaPatiromer Calcium Sorbitex | 32 | $63,189 |
| JardianceEmpagliflozin | 47 | $35,520 |
| LokelmaSodium Zirconium Cyclosilicate | 35 | $34,202 |
| FarxigaDapagliflozin Propanediol | 32 | $21,796 |
| Sevelamer Carbonate | 109 | $21,522 |
| EliquisApixaban | 18 | $9,665 |
| Bumetanide | 121 | $4,448 |
| Potassium Citrate ErPotassium Citrate | 14 | $1,570 |
| Midodrine Hcl | 26 | $1,523 |
| Potassium Chloride | 83 | $1,457 |
| Furosemide | 468 | $1,430 |
| Clonidine | 11 | $1,040 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $4,830 | $71,58016 claims |
| AstraZenecaLokelma, Farxiga | $345 | $55,99867 claims |
| Boehringer IngelheimJardiance | $107 | $35,52047 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 253 nephrology providers in Missouri.
Other nephrology in Springfield
- Susan WoodySpringfield$5K
- David SommerfeldSpringfield$3K
- Derek LarsonCreve Coeur$605K
- Marcos RothsteinSaint Louis$350K
- Anuja JavaSaint Louis$240K
- Kevin MartinSt Louis$189K
- Alejandro AlvarezFlorissant$176K
- Gary SingerSaint Peters$170K
- Daniel CoyneSaint Louis$163K
- Tarek AlhamadSaint Louis$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.